Gainers

• Oragenics (AMEX:OGEN) stock increased by 30.2% to $0.46 during Thursday's after-market session. The market value of their outstanding shares is at $1.5 million.
• InspireMD (NASDAQ:NSPR) shares rose 13.88% to $0.88. The company's market cap stands at $37.4 million. As per the press release, Q3 earnings came out today.
• Instinct Bio Technical Co (NASDAQ:BIOT) stock rose 13.33% to $0.21. The company's market cap stands at $5.8 million.
• EyePoint (NASDAQ:EYPT) shares moved upwards by 9.54% to $0.35. The company's market cap stands at $30.7 million. As per the press release, Q3 earnings came out today.
• China SXT Pharmaceuticals (NASDAQ:SXTC) stock moved upwards by 9.52% to $2.99.
• Can Fite Biopharma (AMEX:CANF) stock rose 9.27% to $1.61. The market value of their outstanding shares is at $3.3 million.

Losers

• Accendra Health (NYSE:ACH) shares fell 6.2% to $0.14 during Thursday's after-market session. The company's market cap stands at $11.0 million.
• Redhill Biopharma (NASDAQ:RDHL) stock declined by 5.23% to $0.36. The market value of their outstanding shares is at $3.2 million.
• Lucid Diagnostics (NASDAQ:LUCD) shares declined by 5.12% to $0.4. The market value of their outstanding shares is at $72.8 million. The company's, Q3 earnings came out today.
• Q32 Bio (NASDAQ:QTTB) stock decreased by 4.77% to $8.4. The company's market cap stands at $275.2 million.
• Arcus Biosciences (NYSE:RCUS) stock decreased by 4.34% to $17.0. The company's market cap stands at $2.3 billion.
• Addex Therapeutics (NASDAQ:ADXN) stock declined by 4.16% to $5.07. See Also: www.benzinga.com/money/best-healthcare-stocks/

This article was generated by Benzinga's automated content engine and reviewed by an editor.

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.